{"filing":{"accession_number":"0001628280-26-061717","cik":"0001048477","ticker":"BMRN","company_name":"BIOMARIN PHARMACEUTICAL INC","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-10","primary_document":"bmrn-20260910.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026061717/bmrn-20260910.htm"},"events":[{"id":33196,"run_id":30517,"accession_number":"0001628280-26-061717","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The disclosure centers on the appointment of Robert Plenge, M.D., Ph.D., to BioMarin's Board of Directors effective September 10, 2026, with assignment to the Science and Technology Committee. While the filing also describes standard director compensation and an RSU grant valued at $400,000, the principal disclosed action is the appointment of a new director to the board, making this an exec_appointment event. Board composition changes are material to investors' assessment of governance and strategic direction.","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36574,"accession_number":"0001628280-26-061717","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the appointment of Robert Plenge, M.D., Ph.D., to BioMarin's Board of Directors effective September 10, 2026, with assignment to the Science and Technology Committee. While the filing also describes standard director compensation and an RSU grant valued at $400,000, the principal disclosed action is the appointment of a new director to the board, making this an exec_appointment event. Board composition changes are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T13:27:41.651889+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36574,"accession_number":"0001628280-26-061717","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the appointment of Robert Plenge, M.D., Ph.D., to BioMarin's Board of Directors effective September 10, 2026, with assignment to the Science and Technology Committee. While the filing also describes standard director compensation and an RSU grant valued at $400,000, the principal disclosed action is the appointment of a new director to the board, making this an exec_appointment event. Board composition changes are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T13:27:41.651889+00:00","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-09-14"}]}